Announcement • Jun 19
Oncoinvent Achieves 50% Recruitment Milestone in Phase 2 Ovarian Cancer Study of Radspherin Oncoinvent announced that its ongoing Phase 2 trial of Radspherin in patients with peritoneal metastases from ovarian cancer has reached the 50% patient recruitment milestone. A total of 54 patients have now been enrolled in the study, representing half of the planned trial population. Recruitment momentum has accelerated significantly in 2026, with 11 patients enrolled in the first quarter and 17 patients recruited in the second quarter to date, marking the high recruitment levels achieved in the study so far. Year-to-date recruitment of 28 patients has already surpassed total enrollment for 2025. Four new sites have opened for recruitment in 2026 and in total ten hospitals across the United States, Spain, Norway, Belgium, the United Kingdom and Italy are currently active in the trial, and further site activations are ongoing to support continued recruitment. The Phase 2 trial (ClinicalTrials.gov: NCT06504147) is a randomized controlled study evaluating the efficacy and safety of Radspherin in patients with peritoneal metastases from ovarian cancer. The primary objective is to compare progression-free survival between patients receiving Radspherin following complete surgical resection and pre-operative chemotherapy, and those receiving standard of care treatment consisting of chemotherapy and surgery alone. Previous Phase 1 and Phase 1/2a data have demonstrated that Radspherin is well tolerated, with no dose-limiting toxicity observed at the recommended dose of 7MBq, and encouraging signals of efficacy. Results from the Phase 1 study in ovarian cancer have been published in the peer-reviewed journal Gynecologic Oncology, and results from the Phase 1/2a study in colorectal cancer have been published in the peer-reviewed journals Journal of Surgical Oncology and Frontiers in Medicine. Reported Earnings • Apr 24
Full year 2025 earnings released: kr1.25 loss per share (vs kr152 loss in FY 2024) Full year 2025 results: kr1.25 loss per share. Revenue: kr28.1m (up 246% from FY 2024). Net loss: kr155.1m (loss widened 11% from FY 2024). Revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Pharmaceuticals industry in Europe. Announcement • Mar 20
Oncoinvent Secures New Patent Expanding Protection for Radspherin Oncoinvent announced that the China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin®, the Company's lead product candidate, marking the first approval worldwide within this patent family. The newly granted patent covers a key technical development to optimize Radspherin's® performance, specifically the size-controlled calcium carbonate microparticle technology. With this grant, patent protection for Radspherin® in China is expanded in scope and duration, with a term extending to 2041. This complements the existing composition-of-matter patent, which is valid until 2035 (2036 in some jurisdictions). Corresponding patent applications from the same patent family remain under review in several major jurisdictions worldwide. 
